Lyna Haybout

University of Helsinki — Finland

Biochemistry, Genetics and Molecular Biology · Life Sciences

6h-index108citations44works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(42), Cancer Research and Treatments(32), CAR-T cell therapy research(24), Viral Infectious Diseases and Gene Expression in Insects(18), Immunotherapy and Immune Responses(4)

Publications44 total

Dyslipidemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumors
Molecular Therapy·2026Open Access
514 Biomarker insights and long-term outcomes of TILT-123 oncolytic adenovirus combined with tumor-infiltrating lymphocytes in refractory metastatic melanoma: results from the TUNINTIL phase 1 trial
Regular and Young Investigator Award Abstracts·2025Open Access
Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models
Cancer Immunology Immunotherapy·2025· 2 citedOpen Access
Neutralizing antibodies and lymphocyte count as biomarkers in patients receiving oncolytic adenovirus TILT-123 and adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic melanoma refractory to immune checkpoint inhibitors.
Journal of Clinical Oncology·2025· 1 cited
Assessment of tumors, blood, and ascites to establish correlations with treatment benefit in platinum resistant or refractory ovarian cancer patients treated with igrelimogene litadenorepvec and pembrolizumab combination therapy.
Journal of Clinical Oncology·2025
Abstract 2035: Clinical-immunological correlates in platinum resistant or refractory ovarian cancer patients treated with chimeric oncolytic adenovirus encoding TNFa and IL-2 (TILT-123) in combination with pembrolizumab
Cancer Research·2025
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes
Cancer Gene Therapy·2025· 2 citedOpen Access
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma
Molecular Therapy Oncology·2025· 3 citedOpen Access
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma
Cell Reports Medicine·2025· 9 citedOpen Access
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial
Nature Communications·2025· 15 citedOpen Access
Safety And Immunological Activity Of A Oncolytic Adenovirus Expressing TNFa And IL-2 In Combination With Pembrolizumab In Platinum-Resistant Or Refractory Ovarian Cancer Patients
International Journal of Gynecological Cancer·2025
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial
Journal for ImmunoTherapy of Cancer·2025· 5 citedOpen Access
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors
Journal of Experimental & Clinical Cancer Research·2024· 13 citedOpen Access
722 Immunoprofiling and correlative analysis from PROTA: a phase I trial combining an oncolytic adenovirus encoding TNFα and IL2 with pembrolizumab for platinum-resistant or refractory ovarian cancer
Regular and Young Investigator Award Abstracts·2024Open Access
Figure 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Supplementary Data 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Table 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 3 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 4 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
page 1 of 3Next →

Frequent Co-authors

Tatiana V. Kudling(44), Elise Jirovec(43), Akseli Hemminki(43), James H.A. Clubb(42), Santeri A. Pakola(41), João M. Santos(41), Víctor Cervera-Carrascón(38), Suvi Sorsa(37), Dafne C.A. Quixabeira(36), Tuomo Alanko(33), Riikka Havunen(32), Jorma Sormunen(28), Claudia Kistler(28), Mirte van der Heijden(24), Katriina Peltola(23), Riitta Korpisaari(22), Susanna Juteau(22), Marjut Jaakkola(22), Victor Arias(20), Annabrita Hemmes(19)